Questionnaire

In the pivotal phase II study of brentuximab vedotin in R/RHL, response rate was achieved with this therapy was?

Brentuximab vedotin works by disrupting the microtubule network, triggering an immune response, resulting in the apoptotic death of the CD30 – expressing tumour cell.

The treatment of advanced – stage Hodgkin Lymphoma (AS-cHL) with BrECADD in the German GHSG HD21 trial resulted in a two-year progression free survival (PFS) rate at 2 years of:

What is the commonly accepted relapse rate for patients with cHL following modern frontline therapy:

In the salvage treatment of refractory HL with modern novel therapies as salvage treatment, after a median-follow-up of 52 months, the overall 4-year survival was?

In a 5-year follow-up of R/R HL patients treated with dose-dense BV combined with ICE, the progression free survival rate was?

In 73 patients with a metabolic CR and then treated with BV-consolidation therapy within the BRESELIBET trial, results showed that this approach can provide a substitute for ASCT in these patients that achieve a mCR after salvage therapy.

In a registry study of patients with high-risk R/R cHL receiving BV maintenance after ASCT, highlighted which of the following factors as being associated with better PFS:

In the final results of the BRESELIBET trial, salvage treatment for RR cHL with BV -ESHAP showed metabolic complete remission rates of?

BV – based regimens have the longest follow-up and show that PET-adapted BrECADD at 48 months has 2^nd cancer rates of

In the HD21 trial, comparing treatment arms for newly diagnosed advanced-stage cHL, which of the following observations was made regarding CIPN-related sensory symptoms and overall health?

In the treatment of patients with advanced Hodgkin Lymphoma (aHL), which of the following statements accurately reflects the findings comparing A+AVD (E1) and PET-guided ABVD (SWOG S0816 and RATHL)?